Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Jul. 26, 2012, 4:11 PM
    Amgen (AMGN): Q2 EPS of $1.61 beats by $0.07. Revenue of $4.48B (+13% Y/Y) beats by $400M. Shares +3.4% AH. (PR)
    | Jul. 26, 2012, 4:11 PM | Comment!
  • Jul. 26, 2012, 12:10 AM
    Notable earnings after Thursday's close: AMGN, AMZN, APKT, ARBA, CA, CB, CBL, CERN, CINF, CLWR, CSTR, DECK, EXPE, FB, FBHS, GILD, HGSI, IM, INFA, KEG, KLAC, LEG, MCK, MXIM, PFG, QLGC, QLIK, RGC, RSG, SBUX, SPF, TLAB, UHS, VRSN
    | Jul. 26, 2012, 12:10 AM | Comment!
  • Jul. 25, 2012, 5:35 PM
    Notable earnings after Thursday's close: AMGN, AMZN, APKT, ARBA, CA, CB, CBL, CERN, CINF, CLWR, CSTR, DECK, EXPE, FB, FBHS, GILD, HGSI, IM, INFA, KEG, KLAC, LEG, MCK, MXIM, PFG, QLGC, QLIK, RGC, RSG, SBUX, SPF, TLAB, UHS, VRSN
    | Jul. 25, 2012, 5:35 PM | Comment!
  • Jul. 19, 2012, 6:06 PM
    Amgen (AMGN) declares $0.36/share quarterly dividend, in line with previous. Forward yield 1.8%. For shareholders of record Aug 16. Payable Sep 07. Ex-div date Aug 14. (PR)
    | Jul. 19, 2012, 6:06 PM | Comment!
  • Jul. 16, 2012, 10:39 AM
    Amgen (AMGN +0.3%) bucks a weak tape on positive comments out of Baird this morning ahead of its Q2 report. The firm says it's anticipating the company to beat expectations, citing its strong operational upside and insulation from weak macro conditions. Stock momentum should also be aided by additional stockholder incentives such as dividend raises and buybacks, and it raises its price target to $79 from $75.
    | Jul. 16, 2012, 10:39 AM | Comment!
  • Jun. 20, 2012, 5:06 PM
    West Pharmaceutical Services (WST) announces an agreement with Amgen (AMGN) to evaluate Daikyo Crystal Zenith technologies for drug containment. The technology was developed by West's partner, Daikyo Seiko. No further details of the agreement were disclosed.
    | Jun. 20, 2012, 5:06 PM | Comment!
  • May 17, 2012, 11:05 AM
    GSK, J&J (JNJ) and Amgen (AMGN) yesterday released positive results from small trials of cancer drugs ahead of a big industry meeting in early June. GSK combined two melanoma medicines, JNJ's already approve Zytiga helped eliminate prostate cancer that hadn't yet spread, and Amgen has revived the once discarded rilotumumab for treating gastric cancer.
    | May 17, 2012, 11:05 AM | Comment!
  • Apr. 27, 2012, 4:04 AM
    The FDA rejects Amgen's (AMGN) application to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer. It's a blow for Amgen, as analysts see Xgeva and a related osteoporosis drug Prolia as among the most important growth drivers for the company.
    | Apr. 27, 2012, 4:04 AM | Comment!
  • Apr. 25, 2012, 8:14 AM
    Amgen (AMGN) agrees to buy 95.6% of privately-held Turkish company Mustafa Nevzat Pharmaceuticals for an amount that values the firm at $700M. The acquisition will help AMGN expand its operations in the fast-growing Turkish market and surrounding region (also: earnings). AMGN +1.3% premarket.
    | Apr. 25, 2012, 8:14 AM | Comment!
  • Apr. 24, 2012, 5:11 PM
    More on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins. Combined sales of Neulasta and Neupogen +9%, Xgeva +14%, and Prolia +9%. Operating margins rose to 36.4% from 34.9%.
    | Apr. 24, 2012, 5:11 PM | Comment!
  • Apr. 24, 2012, 4:13 PM
    Amgen (AMGN): Q1 EPS of $1.61 beats by $0.16. Revenue of $4.05B (+9% Y/Y) beats by $120M. (PR)
    | Apr. 24, 2012, 4:13 PM | Comment!
  • Apr. 10, 2012, 8:52 AM
    Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it widespread rights for kidney disease treatment KAI-4169. As part of the agreement between the firms, Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to the transaction closing.
    | Apr. 10, 2012, 8:52 AM | Comment!
  • Apr. 2, 2012, 4:39 PM
    Amgen (AMGN) and AstraZeneca (AZN) have agreed to collaborate on the development and commercialization of 5 drugs in Amgen's clinical inflammation porfolio. AstraZeneca will lead the way in developing 3 of the 5 drugs.  AstraZeneca will make a $50M one-time payment to Amgen, as well as royalty payments following commercialization.
    | Apr. 2, 2012, 4:39 PM | 1 Comment
  • Mar. 27, 2012, 3:12 PM
    Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed product. Competitor Amgen (AMGN +0.5%) also trades higher.
    | Mar. 27, 2012, 3:12 PM | Comment!
  • Mar. 26, 2012, 12:14 PM
    Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but were upstaged at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.
    | Mar. 26, 2012, 12:14 PM | Comment!
  • Mar. 26, 2012, 6:53 AM
    Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human monoclonal antibody AMG 145. The treatment reduces so-called bad cholesterol by up to 81%, according to data. Phase II results are due out later this year as Amgen tries to shoulder into the high-stakes Lipitor vs. generics battle.
    | Mar. 26, 2012, 6:53 AM | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States